- Milligan JF, Jones RJ, Froehler BC, Matteucci MD. Development of antisense therapeutics. Implications for cancer gene therapy. Ann N Y Acad Sci 1994; 716: 228–241.
- Agrawal S, Temsamani J, Galbraith W, Tang J. Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 1995;28: 7–16.
- Leeds JM, Graham MJ, Truong L, Cummins LL. Quantitation of phosphorothioate oligonucleotides in human plasma. Anal Biochem 1996;235: 36–43.
- Geary RS, Leeds JM, Henry SP, Monteith DK, Levin AA. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 1997;12: 383–393.
- Gardner WD, White PJ, Hoch SO. Identification of a major human serum DNA-binding protein as beta 1H of the alternative pathway of complement activation. Biochem Biophys Res Commun 1980;94: 61–67.
- Galbraith WM, Hobson WC, Giclas PC, Schechter PJ, Agrawal S. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 1994;4: 201–206.
- Sheehan JP, Lan HC. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 1998;92: 1617–1625.
- Henry SP, Monteith D, Levin AA. Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 1997;12: 395–408.
- O'Brian C, Vogel VG, Singletary SE, Ward NE. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 1989;49: 3215–3217.
- Nemunaitis J, Holmlund JT, Kraynak M, Richards D, Bruce J, Ognoskie N, Kwoh TJ, Geary R, Dorr A, Von Hoff D, Eckhardt SG. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J Clin Oncol 1999;17: 3586–3595.
- Aoki K, Yoshida T, Matsumoto N, Ide H, Sugimura T, Terada M. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Mol Carcinog 1997;20: 251–258.
- Chen G, Oh S, Monia BP, Stacey DW. Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem 1996;271: 28259–28265.
- Cunningham CC, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Johnston JF, Monia B, Nemunaitis J. A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 2001;92: 1265–1271.
- Friess H, Kleeff J, Korc M, Buchler MW. Molecular aspects of pancreatic cancer and future perspectives. Dig Surg 1999;16: 281–290.
- Marais R, Light Y, Paterson HF, Marshall CJ. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J 1995;14: 3136–3145.
- Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J, Rapp UR. The ins and outs of Raf kinases. Trends Biochem Sci 1994;19: 474–480.
- Riva C, Lavieille JP, Reyt E, Brambilla E, Lunardi J, Brambilla C. Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance. Eur J Cancer B Oral Oncol 1995;31B (6): 384–391.
- Britten RA, Perdue S, Opoku J, Craighead P. Paclitaxel is preferentially cytotoxic to human cervical tumor cells with low Raf-1 kinase activity: implications for paclitaxel-based chemoradiation regimens. Radiother Oncol 1998;48: 329–334.
- Rasouli-Nia A, Liu D, Perdue S, Britten RA. High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity. Clin Cancer Res 1998;4: 1111–1116.
- Warenius HM, Seabra LA, Maw P. Sensitivity to cis-diamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not c-raf-1 protein. Int J Cancer 1996;67: 224–231.
- Investigator's Brochure ISIS 5132 (CGP 69846A). Isis Pharmaceuticals, Inc, 1998.
- Cunningham CC, Holmlund JT, Schiller JH, Geary RS, Kwoh TJ, Dorr A, Nemunaitis J. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2000;6: 1626–1631.
- Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, Cotter FE. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000;18: 1812–1823.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 15, 2002 - Issue 2